


**Committee on Energy and Commerce**  
**U.S. House of Representatives**  
Witness Disclosure Requirement - "Truth in Testimony"  
Required by House Rule XI, Clause 2(g)(5)

<b>1. Your Name:</b> John H. Lynch, MD		
<b>2. Your Title:</b> Professor & Chairman Department of Urology, MedStar Georgetown University Hospital		
<b>3. The Entity(ies) You are Representing:</b> American Urological Association		
<b>4. Are you testifying on behalf of the Federal, or a State or local government entity?</b>	Yes	No X
<b>5. Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2013. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.</b>  Treatment – Decisions and Patient Reported Outcomes in Low Risk Prostate Cancer Co-Investigator - \$4,437		
<b>6. Please attach your curriculum vitae to your completed disclosure form.</b>		

Signature: \_\_\_\_\_



Date: \_\_\_\_\_

11/21/16

GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE

*CURRICULUM VITAE*

FOR

**John Hugh Lynch, MD, MPH**  
Department of Urology  
MedStar Georgetown University Hospital  
3800 Reservoir Road, NW, 1PHC  
Washington, DC 20007-2113

**1. PERSONAL INFORMATION**

**A. Education:**

Undergraduate:	University of Notre Dame, Notre Dame, Indiana B.S., Pre-Professional Studies	1969
Graduate Education:	Georgetown University School of Medicine, Washington, D.C., Doctor of Medicine	1973
Internship:	Surgical Internship, Emory University Atlanta, Georgia	1973-1974
Residency:	General Surgical Residency, Emory University Atlanta, Georgia	1974-1975
	Urology Residency, Georgetown University Washington, D.C.	1975-1979

**B. Professional Experience:**

Instructor, Division of Urology, Georgetown University Hospital, Department of Surgery	1979–1981
Assistant Professor, Division of Urology Georgetown University, Department of Surgery	1981–1986
Associate Professor, Division of Urology Georgetown University	1986–1991
Professor and Chief, Division of Urology, Department of Surgery, Georgetown University	1991–2002

Vice Chairman, Department of Surgery, Georgetown University	1998–1999
Interim Chairman, Department of Surgery	1999 –2002
Interim Chairman, Department of Urology	2001– 2002
Chairman, Department of Urology	2002–Present
Active Staff, Georgetown Hospital	1979-Present
Active Staff, Sibley Hospital	1979-Present
Consultant in Urology, St. Elizabeth's Hospital	1979-1982
Consultant in Urology, V.A. Hospital	1979-Present
Consultant in Urology, Walter Reed Army Medical Center	1988, 1991

### **C. Licensure:**

State: District of Columbia (DC)

[REDACTED]  
[REDACTED]  
[REDACTED]

[REDACTED]  
[REDACTED]  
[REDACTED]

### **D. Certification:**

Board Certification: American Board of Urology

Date of Certification: 1981

## **2. RESEARCH AND SCHOLARLY ACTIVITIES**

### **A. Publications:**

Lynch JH, Maxted WC. Use of Ephedrine in the Treatment of Post Lymphadenectomy Ejaculatory Failure. Journal of Urology, 129-379, 1983.

Stanton MJ, Lynch JH, Maxted WC, Chun BK. Malacoplakia of the Bladder: A Case Report of Resolution with Bethanechol, Trimethoprim-Sulfamethoxazole and Ascorbic Acid. Journal of Urology, 130:1174, 1983.

Dougherty WE, Lynch JH, Maxted WC. Case Report: Complete Response of Metastatic Transitional Cell Carcinoma of the Bladder with Chemotherapy Alone. Journal of Urology, 131:340, 1984.

Slack NH, Brady MF, Murphy GP. and Investigators in the National Prostatic Cancer Project. Stable versus Partial Response in Advanced Prostatic Cancer. The Prostate, 5:401, 1984.

Slack NH, Murphy GP and Participants in The National Prostatic Cancer Project. Criteria for Evaluating Patient Response to Treatment Modalities for Prostatic Cancer. Urologic Clinics of North America -- II,2, 1984.

Lynch JH, and Maxted WC. Hepatic Dysfunction Associated with Non-Metastatic Renal Cell Carcinoma. Cancer of the Kidney - Chapter 4 - Thieme - Stratton Inc., New York, 1984.

Slack NH, Brady MF, Murphy GP and Investigators in the National Prostatic Cancer Project. A Re-Examination of the Stable Category in Evaluating Response in Patients with Advanced Prostate Cancer. Cancer: 54:564, 1984.

Choyke PL, Thickman D, Kressl HY, Lynch JH, Zeman RK, Jaffe M H, Clark LR. Controversies in the Management of Pelvic Malignancies. Radiologic Clinics of North America 9, 1985.

Killian CS, Yang N, Kuriyama M, Vargas FP, Emrich LJ, Slack NH, Wang MC, Papsidero LD, Murphy GP, Chu TM and Investigators in the National Prostatic Cancer Project. Prognostic Importance of Prostatic-Specific Antigen for Monitoring Patients with Localized Prostate Cancer. Cancer Research 1985.

Killian CS, Yang N, Emrich LJ, Vargas FP, Kuriyama M, Wang MC, Slack NH, Papsidero LD, Murphy GP, Chu TM and the Investigators of the National Prostatic Cancer Project. Prognostic Importance of Prostatic - Specific Antigen for Monitoring Patients with States B2-D2 Prostate Cancer. Cancer Research 1984.

Murphy GP, Slack NH and Participating Investigators of the National Prostatic Cancer Project. Proceedings of the 13th International Congress of Chemotherapy, Vienna, Austria, 1983.

Murphy GP, Slack NH, Karr JP and Participants in the National Prostatic Cancer Project. "Proceedings of the International Symposium in the Management of Prostate Cancer." Overview of the Cooperative Clinical Trials of the USA, National Prostatic Cancer Project. Milano, 1983.

Murphy GP, Slack NH, Mittelman A and Participating Investigators of the National Prostate Cancer Project. Experiences with Estramustine Phosphate in Prostate Cancer. Seminars on Oncology X:3, 34, 1983.

Elder JS, Gibbons RP and Participants in the National Prostatic Cancer Project - Therapeutic Principles in Metastatic Prostate Cancer. Results of Trials of the USA National Prostatic Cancer Project. EORTC Genitourinary Group Monograph 2, Part A. p 427. Alan R. Liss, New York, 1985.

O'Brien W, Lynch JH, Choyke P. Invasion of the Inferior Vena Cava by Testicular Seminoma: Demonstration by Computed Tomography and Venography. Urologic Radiology 8, 108-111, 1986.

O'Brien W, Lynch JH. Thrombosis of the Inferior Vena Cava by Seminoma. *Journal of Urology* 137: 303-305, 1987.

Rotolo JE, O'Brien W, Lynch JH. Renal Cell Carcinoma - A Review. *Hospital Practice*, 2/87.

O'Brien W, Lynch JH. Adrenal Metastases by Renal Cell Carcinoma - Incidence at Nephrectomy. *Urology*, 4/87.

O'Brien W, Choyke P, Copeland J, Klappenbach S, Lynch JH. Adrenal Abscess in an Adult: Demonstration by Computed Tomography. *Journal of Computed Axial Tomography*: 11(3), 550-551, 5/87.

Dejter SW, Lynch JH. Characterization of the Secretory Pattern of Human Prostatic Acid Phosphatase: A Reassessment. *Urology*: 31-125, 1988.

O'Brien W, Lynch JH. Hydroxyproline as a Marker in Patients with Metastatic Prostate Cancer. *Journal of Urology* 139:66-68, 1988.

O'Brien W, Lynch JH. Current Approaches to Prostate Cancer. *Hospital Practice*, 23:1, 1/1988.

Dejter SW, Zuckerman ME, Lynch JH. Benign Villous Polyp with Prostatic-Type Epithelium of Penile Urethra. *Journal of Urology*, 139-590, 1988.

Hafermann MD, Gibbons RP, Murphy GP and Investigators of National Prostatic Cancer Project. Quality Control of Radiation Therapy in Multi-Institutional Randomized Clinical Trial for Localized Prostate Cancer. *Urology* 31:5, 119-124, 1988.

de Kernion JN, Murphy GP, Prine R and Investigators of the National Prostatic Cancer Project. Comparison of Flutamide and Emcyt and in Hormone-Refractory Metastatic Prostatic Cancer. *Urology* 31:312, 1988.

O'Brien W, Lynch JH. *Decision Making in Oncology*, ed. by P. Schein. B.C. Decker, Inc., Philadelphia, 1989.

Genitourinary Cancer -

Renal Cell Carcinoma

Prostate Cancer

Bladder Cancer

Testis Tumors

Tumors of Renal Pelvis and Ureter

Penile Carcinoma

Urethral Carcinoma

O'Brien W, Lynch JH. Epididymitis: An Unusual Presentation of Colovesical Fistula Secondary to Diverticulitis. *Dis. of the Colon & Rectum* 31:570-572, 1988.

O'Brien W, Lynch JH. The Acute Scrotum. *American Family Physician* 37(3):239-247, 1988.

Huben R and Investigators of the National Prostatic Cancer Treatment Group. Buserelin vs. DES or Orchiectomy in the Treatment of Patients with Newly Diagnosed Metastatic Prostate Cancer. *Cancer* 52:1887, 1988.

Zeman RK, Crinan JJ, Rosenfield AT, Lynch JH, Jaffe M H, Clark LR. Renal Cell Carcinoma: Dynamic Thin-Section CT Assessment of Vascular Invasion and Tumor Vascularity. *Radiology* 167 (2):393-396, 1988.

Dejter S W, Cummingham RE, Noguchi PD, Jones RY, Moul JW, McLeod DG, Lynch JH. Prognostic Significance of DNA Ploidy in Carcinoma of Prostate. *Urology* 33:5, 361, 1989.

O'Brien W, Lynch JH. Priapism: Current Concepts and Management. *Annals of Emergency Medicine* 18:9, 1989.

Djakiew D , Tarkington MA, Lynch JH. Paracrine Stimulation of Polarized Secretion from Monolayers of a Neoplastic Prostate Epithelial Cell Line by Prostatic Stromal Cell Proteins. *Cancer Research* 50: 1966-1974, 1990.

O'Brien W, Lynch JH. Simplification of Double-Dye Test to Diagnose Various Types of Vaginal Fistulas. *Urology* 36:5, 456, 1990.

Lynch JH. Uric Acid. *World Book Encyclopedia* (by invitation) 1991.

Djakiew D, Delsite R, Pflug B, Wrathall J, Lynch JH, Onoda M. Paracrine Regulation of Human Prostatic Growth Between a Neoplastic Epithelial Cell Line (TSU-prl) and Stromal Cells by a Nerve Growth Factor-Like Protein. *Cancer Research* 51:3304, 1991.

Djakiew D, Pflug B , Delsite R, Lynch JH, Onoda M. Density Dependent Polarized Secretion of a Prostatic Epithelial Cell Line. *Prostate* 20;15-27, 1992.

Graham CW, Lynch JH, Djakiew DJ. Distributions of Nerve Growth Factor-Like Protein and Nerve Growth Factor Receptor in Human Benign Prostate Hyperplasia and Prostatic Adenocarcinoma. *Urology* 147:5, 1992.

Pflug B, Onoda M, Lynch JH, Djakiew D. Reduced Expression of the Low Affinity Nerve Growth Factor Receptor in Benign and Malignant Human Prostate Tissue and Loss of Expression in Four Human Metastatic Prostate Tumor Cell Lines. *Cancer Research* 52:5403-5406, 1992.

Lynch JH, Graham CW. Management of Stage C Adenocarcinoma of the Prostate. *British J. Urology* 70, Suppl. 1, 50-56, 1992.

Djakiew D, Pflug BR, Delsite R, Onoda M, Lynch JH, Arand G, Thompson EW. Chemotaxis and Chemokinesis of Human Prostate Tumor Cell Lines in Response to Human Prostate Stromal Cell Secretory Proteins Containing a Specific Nerve Growth Factor-Like Protein. *Cancer Research* 53: 1416-1420, 1993.

Lynch JH. Treatment of Advanced Prostate Cancer. *Journal of Family Practice* 35:5, 488, 1993.

Tarkington M A , Sommers C, Gelmann E, Lynch JH. Effect of pH on the Cytotoxicity of Various Chemotherapeutic Agents In Vivo in Superficial Transitional Cell Carcinoma. *Journal of Urology* 147:2, 511, 1993.

Blute ML, Tomera KM, Hellerstein DK, McKiel CF, Lynch JH, Regan JB, Sankey NE. Transurethral Microwave Thermotherapy for Management of Benign Prostatic Hyperplasia: Results of United States Prostatron Cooperative Study. *The Journal of Urology*, Vol. 150; No. 5, Part 2, 1591-1597, November 1993.

Pflug BR, Dionne C, Kaplan DR, Lynch JH, Djakiew D. Expression of a Trk High Affinity Nerve Growth Factor Receptor in the Human Prostate. *Endocrinology*, Vol. 136, No. 1, 262, January 1995.

Rajan R, Vanderslice R, Kapur S, Lynch J, Thompson R, Djakiew D. Epidermal Growth Factor (EGF) Promotes Chemomigration of a Human Prostate Tumor Cell Line and EGF Immunoreactive Proteins are Present at Sites of Metastasis in the Stroma of Lymph Nodes and Medullary Bone. *Prostate* 28:1-9, 1996.

Roberts, BJ., Giblin JG, Tehan TJ, Lynch, JH. Ureteroduodenal Fistula. *Urology* 1996; 48(2): 301-2.

Mordkin RM., Hayes WS., Kuettel MR., Lynch JH. Management of Locally Advanced Prostate Cancer. *Oncology* 1996; 10(9): 1289-300.

Perez M, Regan T, Pflug B, Lynch JH, Djakiew D. Loss of Low-Affinity Nerve Growth Factor Receptor During Malignant Transformation of the Human Prostate. *Prostate* 30: 274-279 (1997)

Gagnon GJ, Harter KW, Berg CD, Lynch JH etd. Limitations Of Irradiated Volume, Equipment And Technique In Conventional Radiation Therapy Of Prostate Cancer's Implications For Unformal 3 D Treatment. *Radiat. Invest* 1997

Couijo M, Badlam GH, Regan JB, Lynch JH, Tomera K, Schimidt R, Calvosa C, Ramsey E, Ligttitrer DJ, Barrett David M. Anew Temporary Catheter (Conticath) For Treatment Of Temporary , Reversible, Postoperative Urinary Retention. *Urology* 53-6, 1999.

Kuettel MR, Parda DS, Harter W, Rodgers JE, Lynch JH. Treatment of Female Urethral Carcinoma in Medically Inoperable Patients Using External Beam Irradiation and High Dose Rate Intracavitary Brachytherapy. *Journal of Urology* 157:1669-1671, May 1997.

Mordkin RM, Dahut WL, Lynch JH. Renal Angiosarcoma: A Rare Primary Genitorurinary Malignancy. (accepted for publication) *Southern Medical Journal*, 4/97.

Lynch, John H., Editor. *Prostatic Disease: Insights and Innovations*. Discovery International. Deerfield, IL, 1997.

Lynch, John H., Prostate Cancer: The Added Factors. Editorial - *JUrol* 1996; 156(1): 144-5.

Lynch, JH. BPH - From Bedside to Bench - Editorial. JUrol 1998; 159(6): 1998.

Lynch, JH (Washington, D.C.); Höfner, K (Hannover). Transurethral Microwave Thermotherapy. Eur Urol 1999; 35:129-137

Joel AB, Lynch JH, "HIFU: An emerging treatment for prostate cancer," Contemporary Urology. 2001; 13 (10): 48-58.

Lynch JH, Batuello RF, Crawford D, Gomella L, Kaufman J, Petrylak J, Joel AB, "Therapeutic strategies for localized prostate cancer." Reviews in Urology. 2001;3 (suppl 2):S39-S48.

Opell MB, Zeng J, Bauer JJ, Connelly RR, Zhang W, Sesterhenn IA, Mun SK, Moul JW, Lynch JH, Investigating the distribution of prostate cancer using three-dimensional computer simulation. 2002; Prostate Cancer and Prostatic Diseases 5,204-208.

Walker, JR, Lynch JH, Testis—"Carcinoma In Situ." Section 2:Urological Diseases and Conditions/185;516-517.

Taylor KL, Shelby RA, Kerner JF, Redd WH, Lynch J. The Impact of Undergoing Prostate Cancer Screening on Prostate Cancer Related Knowledge and Distress. Cancer, 95: 1037, 1044. 2002.

Khwaja F, Allen J, Lynch J, Andrews P, Djakiew D. Ibuprofen Inhibits Survival of Bladder Cancer Cells by Induced Expression of the p75<sup>NTR</sup> Tumor Suppressor Protein. Cancer Research 64, 6207-6213, September 1, 2004.

Lynch JH, Blute ML, Tomera KM, Hellerstein DK, McKiel CF, Sankey NE. Transurethral Microwave Thermotherapy for the Treatment of Benign Prostatic Hypertrophy. One Year Clinical Results of the Prostatron Study Group. J. Endourology - Vol. 7, Oct. 1993.

Lynch JH, Blute ML, Tomera KM, Hellerstein DK, McKiel CF, Sankey NE. Assessment of Symptom Improvement in Transurethral Microwave Thermotherapy for the Treatment of Benign Prostatic Hypertrophy. Comparison of the AUA Symptom Index and Madison Symptom Score in the Clinical Outcome. J. Endourology, Vol. 7, Oct. 1993.

Hayes WS, Sesterhenn IA, Xuan J, Wang Y, Becker RL, Lynch JH, Moul JW, McLeod DG, Losee J, Mun SK, Mostofi FK. Interactive Three-Dimensional Modeling of Localized Prostate Cancer: Computer Simulation of Needle Biopsy Technique. Journal of Urology 157:4;1639A, 4/97.

Roberts BJ, Regan JB, Lynch JH, Lau I, Wang JY, Lo S-CB, Mun SK, Hayes WS. Transurethral Microwave Thermotherapy; Prediction of Treatment Outcome Using Various Analytical Methods. Journal of Urology 157:4; 1706A, 4/97.

Kowalczyk KJ, Choueiri TK, Hevelone ND, Trinh QD, Lipsitz SR, Nguyen PL, Lynch JH, Hu JC. Comparative effectiveness, costs and trends in treatment of small renal masses from 2005-2007. BJU Int. 2013 Aug; 112(4): E273-80.



Chen LN, Suy S, Uhm S, Oermann EK, Ju AW, Chen V, Hanscom HN, Laing S, Kim JS, Lei S, Batipps GP, Kowalczyk K, Bandi G, Pahira J, McGeagh KG, Collins BT, Krishnan P, Dawson NA, Taylor KL, Dritschilo A, Lynch JH, Collins SP. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. *Radiat Oncol.* 2013 mar 13;8:58.

Tsai HT, penson DF, Makambi KH, Lynch JH, Van Den Eeden SK, Potosky AL. Efficacy of intermittent androgen deprivation therapy vs. conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis. *Urology*, 2013 Aug; 82(2):327-33.

Obayomi-Davies O, chen LN, Bhagat A, Wright HC, Uhm S, Kim JS, yung TM, Lei S., Batipps GP, Pahira J, McGeagh KG, Collins BT, Kowwalczyk K, Bandi G, Jumar D, Suy S, Dritschilo A, Lynch JH, Collins SP. Potency preservation following stereotactic body radiation therapy for prostate cancer. *Radiat Oncol.* 2013 Nov 1: 8256.

Vora AA, Marchalik D, Kowalczyk KJ, Nissim H, Bandi G, McGeagh KG, Lynch JH, Ghasemian SR, Verghese M, Venkatesan K, Borges P, Uchio EM, Hwang JJ. Robotic-assisted prostatectomy and open radical retropubic prostatectomy for locally-advanced prostate cancer; multi-institution comparison of oncologic outcomes. *Prostate Int.* 2013; 1(1); 31-6.

Kowalczyk KJ, Gu X, Nguyen PL, Lipsitz SR, Trinh QD, Lynch JH, Collins SP, Hu JC. Optimal timing of early versus delayed sdjuvant radiotherapy following radical prostatectomy for locally advanced prostate cancer. *Urol Oncol.* 2014 Apr; 32(3): 303-8

Bhattasali O, chen LN, Tong M, Lei S, Collins BT, Krishnan P, Kalhorn C, Lynch JH, Suy S, Dritschilo A, Dawson NA, Collins SP. Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-naïve prostate cancer. *Front Oncol.* 2013 Dec 3;3:293.

Bhattasali O, Chen LN, Woo J, park JW, Kim JS, Moures R, Yung T, Lei S, Collins BT, Kowalczyk K, Suy S, Dritschilo A, Lynch JH, Collins SP. Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer. *Radiat Oncol*, 2014 Feb 11; 9:52.

Chen LN, Rubin RS, Othepa E, Cer C, Yun E, Agarwal RP, Collins BT, McGeagh K, Pahira J, Bandi G, Kowalczyk K, Jumar D, Dritschilo A, Collins SP, Bostwick DG, Lynch JH, Suy S. Correlation of HOXD3 promoter hypermethylation with clinical and pathologic features in screening prostate biopsies. *Prostate* 2014 may; 74(7):714-21.

Woo JA, Chen LN, Bhagat A, Oermann EK, Kim JS, Moures R, yung T, Lei S, Collins BT, Kumar D, Suy S, Dritschilo A, Lynch JH, Collins SP. Clinical characteristics and management of late urinary symptom flare following stereotactic body radiation therapy for prostate cancer. *Front Oncol.* 2014 may 26: 4:122.

Chen LN, Suy S, Wang H, Bhagat A, Woo JA, Moures RA, Kim JS, yung TM, Lei S, Collins BT, Kowalczyk K, Dritschilo A, Lynch JH, Collins SP. Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer. *Radiat Oncol.* 2014 June 26;9:148.

Arscott WT, Chen LN, Wilson N, Bhagat A, Kim JS, Moures RA, yung TM, Lei S, Collins BT, Kowalczyk K, Suy S, Dritschilo A, Lynch JH, Collins SP. Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer. *Radiat Oncol*. 2014 Jul 24;9:163.

Rana Z, Cyr RA, Chen LN, Kim BS, Moures RA, yung TM, Lei S, Collins BT, Suy S, Dritschilo A, Lynch JH, Collins SP. Improved irritative voiding symptoms 3 years after stereotactic body radiation therapy for prostate cancer. *Front Oncol*. 2014 Oct 21;4:290.

Joh DY, Chen LN, Porter G, Bhagat A, Sood S, Kim JS, Moures R, Yung T, Lei S, Collins BT, Ju AW, Suy S, Carroll J, Lynch JH, Dritschilo A, Collins SP. Proctitis following stereotactic body radiation therapy for prostate cancer. *Radiat Oncol*. 2014 Dec 12;9:277.

Woo JA, Chen LN, Wang H, Cyr RA, Bhattasali O, Kim JS, Moures R, Yung TM, Lei S, Collins BT, Suy S, Dritschilo A, Lynch JH, Collins SP. Stereotactic body Radiation Therapy for Prostate cancer: What is the appropriate patient-reported outcome for Clinical Trial Design? *Front Oncol* 2015 mar 31;5:77.

Gurka MK, chen LN, Bhagat A, Coures R, Kim JS, yung T, Lei S, Collins BT, Krishnan P, Suy S, Dritschilo A, Lynch JH, Collins SP. Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer. *Radiat Oncol*. 2015 Feb 19;10:44.

Janowski EM, Kole TP, Chen LN, Kim JS, Yung TM, Collins BT, Suy S, Lynch JH, Dritschilo A, Collins SP. Dysuria following stereotactic body radiation therapy for prostate cancer. Paydar I, Kim BS, Cyr RA, Rashid H, Anjum A, Yung TM, Lei S, Collins BT, Suy S, Dritschilo A, Lynch JH, Collins SP. Urethrogram-directed stereotactic body radiation therapy for clinically localized prostate cancer in patients with contraindications to Magnetic Resonance Imaging. *Front Oncol*. 2015 Sep 1;5:194.

Tsai HT, Penson D, Luta G, Lynch JH, Zhou Y, Potosky AL. Adoption of intermittent androgen deprivation therapy for advanced prostate cancer: A population based study in American urology Practice. *Urol Pract*. 2015 Jul; 2(4): 190-198.

Mercado C, Kress MA, Cyr RA, Chen LN, Yung TM, Bullock EG, Lei S, Collins BT, Satinsky AN, Harter KW, Suy S, Dritschilo A, Lynch JH, Collins SP. Intensity-modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: The Georgetown University Experience. *Front Oncol*. 2016 May 6;6:114.

#### **b. Other Publications/Presentations**

Oxygen Consumption in Sodium Depleted Rats, Georgetown Medical School, 1972

Urologic Evaluation of Infants, Washington Urology Society - Mid-Atlantic AUA, 1977

Renal Pseudotumor - Etiology & Diagnosis, Washington Urology Society, 1978

Renal Oncocytomas, Mid-Atlantic AUA, 1981

Use of Ephedrine in the Treatment of Post Lymphadenectomy Ejaculatory Failure, Mid-Atlantic AUA, 1982

Retroperitoneal Lymphangiomatosis - Mid-Atlantic AUA, 1982

Treatment of Metastatic Transitional Cell Carcinoma with Combination Chemotherapy - Mid-Atlantic AUA, 1982

Testicular Carcinoma - Grand Rounds, DeWitt Army Medical Center, 1983

Hepatic Dysfunction Associated with Renal Cell Carcinoma, Mid-Atlantic AUA, 1983

Management of Bladder Cancer, Panel Discussion, Urological Surgery Symposium - 1983, Washington, D.C.

The Value of Hydroxyproline as a Marker of Bony Metastases in Patients with Metastatic Adenocarcinoma of the Prostate - New York AUA, 1984.

Pudendal Nerve Evoked Response During Radical Prostatectomy - Assessment of Sexual Function, Mid-Atlantic AUA, 1984

Epidemiology and Treatment of Renal Cell Cancer Renal Pelvic Cancer, NCI Cancer Control Program, 1985-88.

Hydroxyproline as a Marker Prostate Cancer, Mid-Atlantic AUA, 1986

Alternate Forms of Urinary Diversion, ACS - All Surgeon's Day - 1987, Washington, D.C.

Diurnal Variation of PSA & PAP in Benign and Malignant Disease of the Prostate, New York Section AUA, 1987.

Flow Cytometry in the Evaluation of Prostate Cancer, Kimbrough Urologic Society - 1987, Washington, D.C.

Alternate Forms of Urinary Diversion, Mid-Atlantic Enterostomal Society - 1987, Columbia, Maryland.

Update on Urologic Oncology - 1988, Maryland Family Practice Association, Solomon's Island, Maryland.

Update on Bladder and Prostate Cancer - 1988, Williamsburg, Virginia.

Advances in the Treatment of Prostate Cancer, Baltimore, Maryland, 1989.

Flutamide in the Treatment of Prostate Cancer, New England Medical Center, 1989.

Update on Urologic Oncology, Shady Grove Hospital Grand Rounds - 1989,

Rockville, Maryland.

Current Perspectives in Prostate Cancer, Norfolk Urology Society -1989, Norfolk, Virginia.

Use of Flutamide in the Treatment of Prostate Cancer, SUNY - Syracuse Grand Rounds - 1990, Syracuse, N.Y.

Advances in Prostate Cancer, Greater Southeast Hospital, Washington, D.C., 1990.

Management of Advanced Prostate Cancer, Mercy Hospital Grand Rounds - 1990, Baltimore, Maryland.

Therapeutic Approaches in Prostate Cancer, Fairfax Hospital Grand Rounds - 1990, Fairfax, Virginia.

Treatment of Localized Prostate Cancer, Update on Prostate Cancer Conference - 1990, Chantilly, Virginia.

Treatment of Metastatic Prostate Cancer, National Conference on Advances in the Management of Prostate Cancer - 1990, Colorado Springs, Colorado.

Current Perspectives in the Management of Prostate Cancer, SUNY Downstate Grand Rounds - 1990, Brooklyn, N.Y.

Treatment Options in the Management of Advanced Prostate Cancer - Role of Anti-Androgens, Jefferson Medical Center - 1990, Philadelphia, Pennsylvania.

Treatment of Localized Prostate Cancer, Current Perspectives in the Management of Prostate Diseases - 1990, Washington, D.C.

Alternative Treatment Options in Metastatic Prostate Cancer, National Conference on Advances in the Treatment of Prostate Diseases, Toronto, Canada, 1990.

Recent Advances in the Diagnosis and Management of Prostate Cancer, Franklin Square Hospital Grand Rounds, Baltimore, Maryland, 1990.

Medical/Surgical Management of Advanced Prostate Cancer, National Conference - Progress Report on the Clinical Treatment of Prostate Cancer, Scottsdale, Arizona, 1990.

Surgical Treatment of Localized Prostate Cancer, Regional Conference - Diagnosis and Treatment of Prostate Cancer - Orlando, Florida, 1991.

Treatment Options for Locally Advanced Prostate Cancer, Regional Conference - Diagnosis and Treatment of Prostate Cancer, Orlando, Florida, 1991.

Treatment Options for Locally Advanced Prostate Cancer, Post-Graduate Course - AUA Meeting, Toronto, Canada, 1991.

Transurethral Microwave Thermotherapy in BPH - U.S. Results - Second International Prostatron Conference, Sevilla, Spain, 1991.

American Experience with Complete Androgen Blockade, Canadian Urologic Society Meeting, Whistler, B.C., 1992.

Current Management of Prostate Cancer, Crested Butte, Colorado, 1992.

Treatment Options for Treatment of Benign Prostatic Hypertrophy, Crested Butte, Colorado, 1992.

Rationale for Use of Alpha-Adrenergic Agents in the Treatment of Benign Prostatic Hypertrophy, Pasadena, California, 1992.

Treatment of Locally Advanced Prostate Cancer, Post-Graduate Course - AUA Meeting, Washington, D.C., 1992.

Radiation vs. Surgery in the Treatment of Localized Prostate Cancer - Stamford, Connecticut, 1992.

Transurethral Microwave Thermotherapy - in BPH - U.S. Results, Third International Prostatron Conference, Tokyo, Japan, 1992.

Update on Prostate Cancer - Montgomery General Hospital Medical Staff Conference, 10/92.

Medical Management of BPH - Washington Hospital Center Medical Staff Conference, 10/92.

Treatment Options for BPH - Brooklyn, Long Island, Queens Urologic Society, New York, 12/92.

Medical Treatment Alternatives in BPH - Fort Meade Medical Staff Conference, 3/93.

Treatment Alternatives for BPH - Group Health Associations Medical Staff Conference, 3/93.

Nosocomial UTIs - Georgetown Clinical Society, Park City, Utah, 1/93.

Role of PSA in Prostatic Diseases - Georgetown Hospital, Department of Medicine Grand Rounds, 3/93.

Screening for Prostate Cancer and the Role of Prostatectomy in the Management of Patients with Localized Prostate Cancer, Good Samaritan Hospital Conference on Prostate Cancer, Cincinnati, Ohio, 3/93.

Screening, Staging and Surgery in Prostate Cancer, Georgetown Radiation Therapy Update Conference, 4/93.

Prostate Cancer - Current Management, Laurel Hospital Medical Staff Conference, 4/93.

Treatment Options for BPH, Harrisonburg Hospital, Harrisonburg, Virginia, 4/93.

Medical Management of BPH, Calvert County Memorial Hospital Medical Staff Conference, 5/93.

Treatment Alternatives for BPH, Lewis Gale Hospital, Salem, Virginia, 6/93.

Update on Prostate Cancer, Doctor's Hospital, Lanham, Maryland, 5/93.

Treatment of Metastatic Prostate Cancer, Middlesex Memorial Hospital, Middletown, Connecticut, 6/93.

Role of Surgery in Prostate Cancer, Alexandria Hospital Conference on Prostate Cancer, 5/93.

Treatment of Locally Advanced Prostate Cancer, AUA Post-Graduate Course, San Antonio, Texas, 1993.

Transurethral Microwave Thermotherapy: An Alternative for the Treatment of BPH. One Year Clinical Results of the Prostatron Study Group - Podium Presentation. AUA Annual Meeting, San Antonio, Texas, 5/93.

BPH - Treatment Alternatives, Tidewater Urologic Society, Newport News, Virginia, 9/93.

Visiting Professor, Eastern Virginia Medical School, Norfolk, Virginia, 9/93.

Orthopedic Complications of Urinary Diversion, Georgetown Clinical Orthopedic Conference, Park City, Utah, 1/94.

Visiting Professor, University of Witwaterstrand, South Africa, 3/27/94.

Visiting Professor, University of Praetoria, South Africa, 3/28/94.

Age-Adjusted PSA, South Africa Urologic Congress, Praetoria, South Africa, 3/30/94.

Role of Interferon in the Treatment of Bladder and Renal Cancer, San Diego Urology Society, 8/7/94.

Evaluation of Patients with Positive Margins Following Radical Prostatectomy - UCSF, 10/2/94.

Treatment of Superficial Bladder Cancer, Santa Rosa Hospital Tumor Board, San Antonio, Texas, 10/7/94.

Medical Management of BPH, Georgetown Clinical Society, Steamboat Springs, Colorado, 1/28/95.

PSA and the Management of Patients with Prostate Cancer, 4th European Winter Urologic Forum, Davos, Switzerland, 2/22/95.

Terazosin - Results of Clinical Studies, 4th European Winter Urologic Forum, Davos, Switzerland, 2/22/95.

Thermotherapy in BPH, Medivision Videoconference, Columbus, Ohio; Houston, Texas, 2/95.

Role of Intravesical Therapy in Superficial Transitional Cell Carcinoma, Columbus Urologic Society, 3/3/95.

Bladder Cancer: Current Concepts in Superficial Disease, Urologic Grand Rounds, New York, 3/13/95.

Margin Positive Prostate Cancer - Observation or Treatment? University of Colorado Urology Grand Rounds, Denver, Colorado 3/27/95.

Evaluation and Management of BPH, National Association of Managed Care Physicians, Palm Springs, California 5/11/95.

Intravesical Therapy in Bladder Cancer Oncology Conference, SUNY, Brooklyn, New York, 5/26/95.

Prostate Urethral Stents and Thermotherapy in BPH, Initiatives in Prostate Disease, Williamsburg, VA, 6/10/95.

Advanced Prostate Cancer, Initiatives in Prostate Disease, Williamsburg, VA, 6/10/95.

Treatment of Advanced Prostate Cancer, Stoneybrook, SUNY Urology Grand Rounds, Long Island, NY, 6/23/95.

Prostatic Urethral Stent and Thermotherapy: Minimally Invasive Treatment Alternatives in BPH Therapy, Nevis, West Indies, 7/13/95.

Clinical T3 Prostate Cancer - Cure or Palliation, Nevis, West Indies, 7/15/95.

Treatment Options for Prostate Cancer, American Foundation for Urologic Disease Conference, Washington, D.C., 8/25/95.

Visiting Professor, University of South Florida, 9/14/95.

Intravesical Therapy in Bladder Cancer, Tampa Urol. Society, Tampa, Florida, 9/14/95.

Medical Management of BPH, Department of Medicine, National Naval Medical Center, Bethesda, MD, 10/30/95.

Current Concepts in Bladder Cancer, NE Georgia Regional Cancer Center, Gainesville, GA, 12/8/95.

Urologic Complications of Spinal Cord Injury, Georgetown Clinical/Orthopaedic Society, Beaver Creek, Colorado, 1/31/96.

Superficial Transitional Cell Carcinoma: Current Concepts and Treatment. Washington Hospital Center - Cancer Center Grand Rounds, 2/14/96

Watchful Waiting for Prostate Cancer: Pros and Cons. Prostatic Disease: Insights and Innovations, Banff, Canada, 2/29/96

Indications for Nerve-Sparing Radical Prostatectomy. Prostatic Disease: Insights and Innovations, Banff, Canada, 2/9/96

Conservative Management of Prostate Cancer, University of Colorado, 3/22/96.

Visiting Professor, University of Colorado, 3/22/96.

Epidemiology and Natural History of Prostate Cancer, Mid-Atlantic Section AUA Section Seminar, Philadelphia, 3/21/96.

Terazosin in the Treatment of Patients with BPH: Clinical Studies, Philippines National Family Practice Association Meeting, Manila, 4/96.

Current Management of BPH, Winchester Medical Center, 6/5/96.

Superficial Transitional Cell Carcinoma: Current Trends, Louisiana State Urologic Society Annual Meeting, Shreveport, LA, 6/14/96.

Management of Prostate Cancer. Hellenic Surgical Society, Athens, Greece, 11/4/96.

Quality of Life in Prostate Cancer & BPH. Perspectives in Urology, Scottsdale, AZ, 12/3/96.

Minimally Invasive Treatment Options for BPH: A Comparison Between TUMT and TUNA, Perspectives in Urology, Scottsdale, AZ, 12/4/96.

Radical Prostatectomy in the Management of Localized Prostate Cancer, 7<sup>th</sup> Annual International Conference on Prostate Cancer, Beaver Creek, CO, 1/26/97.

Critical Pathways and Quality of Care for Prostate Cancer. 7<sup>th</sup> Annual International Conference on Prostate Cancer, Beaver Creek, CO, 1/27/97.

Transurethral Microwave Thermotherapy for BPH, New Orleans Urologic Society, 3/13/97.

Visiting Professor - Tulane University, 3/13/97.

Transurethral Microwave Thermotherapy for BPH, Tulane University, New Orleans, LA, 3/26/97.

Transurethral Microwave Thermotherapy for BPH, Thomas Jefferson University, Philadelphia, PA, 3/14/97.

Transurethral Microwave Thermotherapy for BPH, Martinsburg, Hospital Grand Rounds, 3/24/97.

Transurethral Microwave Thermotherapy for BPH, Vanderbilt University, Nashville, TN, 4/4/97.



Prostatic Urethral Stents for BPH, American Urological Association Post-Graduate Course on Minimally Invasive Treatment Options for BPH, American Urological Association Annual Meeting, New Orleans, LA, 4/14/97.

Prostatron Therapy for BPH, American Urological Association Post-Graduate Course on Minimally Invasive Treatment Options for BPH, American Urological Association Annual Meeting, New Orleans, LA, 4/14/97.

Outcome Analysis, Critical Pathways and Current Status of Localized Prostate Cancer. Innovations in the Diagnosis and Management of Prostatic Carcinoma, New York, New York, 8/8/97.

Role of Alpha Blockers in the Management of BPH. Landsdowne, VA, 5/98.

Transurethral Microwave Thermotherapy - Indications for Use. World Congress of Endourology, New York, NY. 9/3/98.

Transurethral Microwave Thermotherapy: Hands-On Technique. World Congress of Endourology, New York, NY. 9/5/98.

Comparison of Sextant to 5-Region Biopsy Technique Using a Three-Dimensional Computer Simulation of Actual Prostate Specimens. Mid-Atlantic Section, AUA. Palm Beach, FL. 10/6/98.

Medical Therapy in BPH. Point-Counterpoint Panel. Management of BPH: Surgery VS Medical Therapy. Mid-Atlantic Section, AUA. Palm Beach, FL. 10/7/98.

High Intensity Focused Ultrasound for Prostate Cancer. Inoperative Solutions For Prostate Cancer Care; Image-Guided Minimally Invasive Diagnosis And Treatment – June 5, 1999.

Computer Generated Prostate Biopsies. 10<sup>th</sup> International Prostate Cancer Update. Vail, CO – January 25, 2000.

High Intensity Focused Ultrasound for Prostate Cancer. 10<sup>th</sup> International Prostate Cancer Update. Vail, CO – January 26, 2000.

High Intensity Focused Ultrasound. Management Options for Prostate Cancer in the Year 2000. Arlington, VA – October 27, 2000.

High Intensity Focused Ultrasound for Prostate Cancer. 11<sup>th</sup> International Prostate Cancer Update. Vail, CO. February 2, 2001.

Moderator – Therapeutic Strategies in Localized Prostate Cancer. 11<sup>th</sup> International Prostate Cancer Update. Vail, CO. February 3, 2001.

Transurethral Microwave Thermotherapy. 11<sup>th</sup> International Prostate Cancer Update. Vail, CO. February 4, 2001.

Minimally Invasive Therapies for BPH. Perspectives in Urology  
Denver, CO. November 7-10, 2002

Prostate Biopsies: What Should the Standard Be? 12<sup>th</sup> International prostate Cancer Update Keystone, CO  
February 7, 2002

High Intensity Focused Ultrasound. 12<sup>th</sup> International Prostate Cancer Update  
Keystone, CO February 8, 2002

Transurethral Microwave Thermotherapy for BPH. 12<sup>th</sup> International Prostate Cancer Update. Keystone,  
CO February 10, 2002

Prostate Biopsies: How Many and Where. 9<sup>th</sup> Annual Scottsdale prostate Cancer Symposium.  
Scottsdale, AZ March 3, 2004

Prostate Biopsy Results: Treatment and Planning. A Urologist's perspective.  
9<sup>th</sup> Annual Scottsdale Prostate Cancer Symposium. Scottsdale, AZ March 4, 2004

Defining Local Control Following Radical Prostatectomy. 9<sup>th</sup> Annual Scottsdale Prostate Cancer  
Symposium. Scottsdale, AZ March 4, 2004

High Intensity Focused Ultrasound in the management of newly diagnosed prostate cancer. Bermuda  
Urologic Conference July 22, 2005

High Intensity Focused Ultrasound. Mid-Atlantic Section AUA, Invited Lecturer. Washington, DC,  
October 15, 2006.

Chemotherapy in the Treatment of Metastatic Hormone-Refractory Prostate Cancer. AUA/JUA Meeting,  
Honolulu, Hawaii 2012

Screening for Prostate Cancer, Mexican Urologic Society. Cabo San Lucas 2014

PSA and Diagnostic Tools for Prostate Cancer. Mexico Urologic Society, Cabo San Lucas 2014

**c. Abstracts for Conference papers and posters**

O'Brien W, Lynch JH. Epididymitis: An Unusual Complication of Colovesical Fistula Secondary to  
Diverticulitis, Journal of Urology 1988.

Dejter S, Lynch JH. Flow Cytometric Measurements of Cellular DNA on Paraffin-Embedded Human  
Prostatic Cancer Tissue: Relationship to Gleason Grade, Stage & Survival. Poster Session - AUA  
National Meeting, Anaheim, California, 1987.

Lynch JH. Medical/Surgical Management of Advanced Prostate Cancer, Proceedings from "A Progress  
Report on the Clinical Treatment of Prostate Cancer" 1990.

Graham C, Lynch JH. Management of Stage C Adenocarcinoma of the Prostate, Proceedings from "Controversies in Prostate Cancer - Diagnosis and Treatment" 1991.

Complete Androgen Blockage - American Experience, Proceedings from Canadian Urologic Society Meeting on Prostate Cancer, 1992.

Delsite R, Pflug B, Wrathall JR, Lynch JH, Onoda M, Djakiew D. Nerve Growth Factor (NGF) - Like Protein(s) are Involved in Paracrine Growth Regulation of the Prostate. 73rd Annual Meeting of the Endocrine Society, 1991.

Pflug B, Graham C, Lynch JH, Djakiew D. Identification of the Type II NGF Receptor in the Human Prostate. Seventeenth Annual Meeting of the American Andrology Society, Washington, D.C., 1992.

Djakiew D, Pflug B, Lynch JH, Arand G, Thompson E. Prostatic Stromal Cells Secrete a NGF-like Paracrine Factor which is Chemotactic for a Neoplastic Epithelial Cell Line. Eighty-Seventh Annual Meeting of the American Urological Association, Washington, D.C., 1992.

Pflug B, Lynch J, Djakiew D. Loss of the p75 NGF Receptor in Benign and Malignant Prostate Tissues. International Symposium on Biology of Prostate Growth, Bethesda, Maryland, p74, 1992.

Pflug B, Lynch J, Djakiew D. A high affinity trk-related nerve growth factor receptor is present in human prostate tissues and cell lines. Eighteenth Annual Meeting of the American Andrology Society, Tampa Bay, 1993.

Djakiew D, Pflug B, Delsite R, Onoda M, Lynch J, Arand G, Thompson E. Chemotaxis and chemokinesis of human prostate tumor cell lines in response to human prostate stromal cell secretory proteins containing a nerve growth factor-like protein. Eighty-eighth Annual Meeting of the American Urological Association, San Antonio, 1993.

Hackett KC, Pflug BR, Lynch JH, & Djakiew D. Characterization of human prostate stroma and epithelium in adenocarcinoma, benign prostatic hyperplasia and normal prostate tissue. Fifty-first Annual Meeting of the Mid-Atlantic Section of the American Urological Association, Florida, 1993.

Lynch, JH, Blute ML, Tomera KM, Hellerstein DK, McKiel CF, Stankey NE. Transurethral Microwave thermotherapy for the Treatment of Benign Prostatic Hypertrophy. One year clinical results of the Prostatron Study Group. J. Endourology – Vol. 7, Oct. 1993.

Lynch JH, Blute ML, Tomera KM, Hellerstein DK, McKiel CF, Sankey NE. Assessment of symptom improvement in transurethral microwave thermotherapy for the treatment of Benign Prostatic Hypertrophy. Comparison of the AUA Symptom Index and Madison Symptom Score in the Clinical Outcome. J. Endourology, Vol 7, Oct. 1993.

Rajan RP, Vanderslice RR, Lynch JH, Djakiew D. Potential role of epidermal growth factor in the site specific metastases of prostate cancer. Mid-Atlantic AUA, 9/94.

Lynch JH. Prostatic Stents and Thermotherapy: Minimally Invasive Alternatives in BPH Therapy (abstract). A Commitment to Urology: Therapeutic Innovations in BPH and Prostate Cancer. 7/95.

Lynch JH. Clinical State T3 Prostate Cancer: A Matter of Cure or Palliation (abstract). A Commitment to Urology: therapeutic Innovations in BPH and Prostate Cancer. 7/95.

Joseph E. Oesterling, Ann Arbor, MI, Keith Lloyd, Birmingham, AL, John Lynch, Washington, DC, Robert J. Padley, North Chicago, IL, for the HYCAT Investigator Group (Presentation by Dr. roehrborn), Hytrin Community Assessment Trial (HYCAT): Evaluation of the clinical Effectiveness of Tezazosin versus Placebo in the Treatment of Patients with Symptomatic Benign Prostatic Hyperplasia (BPH). Claus G. Roehrborn, Dallas, TX, 8/95.

Lynch JH. Watchful Waiting: Pros and cons (abstract). Prostatic Diseases: Insights and Innovations. 2/96.

Lynch JH. Indications for Nerve-Sparing Prostatectomy (abstract). Prostatic Diseases: Insights and Innovations. 2/96.

Lynch JH. Alpha-blockers in BPH: Current and future. Videotape. For National Program: urology update: Management of BPH. 2/21/96.

Lynch JH. Epidemiology, Risk Factors & Natural History of Prostate Cancer (abstract). Proceedings from mid-Atlantic Section AUA Seminar. 3/96

Lynch JH. Critical Care Pathways and quality of Life in prostate Cancer and BPH. Proceedings from perspectives in Urology. 12/96

Lynch JH. Minimally Invasive Treatment Options for BPH: TUNA vs TUMT. Proceedings from perspectives in Urology. 12/96.

Lynch JH. Outcome Analysis and Critical pathways for Localized Prostate Cancer. Proceedings from 7<sup>th</sup> International Prostate Cancer Update. 1/97.

Lynch JH. Renal Cell Carcinoma. 1997 International urology Preceptorship program. 3/11/97.

Lynch JH. Superficial Bladder Cancer. 1997 International Urology Preceptorship Program. 3/11/97.

Lynch JH. Transurethral Microwave Thermotherapy. 1997 International Urology Preceptorship. 3/11/97.

Hayes WS, Sesterhenn IA, Xuan J, Wang Y, Becker RL, Lynch JH, Moul JW, McLeod DG, Loses J, Mun SK, Mostofi FK. Interactive Three-Dimensional Modeling of Localized Prostate Cancer: Computer Simulation of Needle Biopsy Technique. Journal of Urology 157:4; 1639A, 4/97.

Rajan RP, Vanderslice RR, Lynch JH, Djakiew D. Potential Role of Epidermal Growth Factor in the Site Specific Metastases of Prostate Cancer. Mid-Atlantic AUA, 9/94.

Prostatic Stents and Thermotherapy: Minimally Invasive Alternatives in BPH Therapy (abstract). A Commitment to Urology: Therapeutic Innovations in BPH and Prostate Cancer, 7/95.

Clinical Stage T3 Prostate Cancer: A Matter of Cure or Palliation (abstract). A Commitment to Urology: Therapeutic Innovations in BPH and Prostate Cancer, 7/95.

Joseph E. Oesterling, Ann Arbor, MI, Keith Lloyd, Birmingham, AL, John Lynch, Washington, DC, Robert J. Padley, North Chicago, IL, for the HYCAT Investigator Group (Presentation by Dr. Roehrborn), Hytrin Community Assessment Trial (HYCAT): Evaluation of the Clinical Effectiveness of Terazosin versus Placebo in the Treatment of Patients with Symptomatic Benign Prostatic Hyperplasia (BPH). Claus G. Roehrborn, Dallas, TX, 8/95.

Watchful Waiting: Pros and Cons (abstract). Prostatic Diseases: Insights and Innovations, 2/96.

Indications for Nerve-Sparing Prostatectomy (abstract). Prostatic Diseases: Insights and Innovations, 2/96.

Alpha-blockers in BPH: Current and Future. Videotape. For National Program: Urology Update: Management of BPH, 2/21/96.

Lynch, JH. Epidemiology, Risk Factors & Natural History of Prostate Cancer (abstract). Proceedings from Mid-Atlantic Section AUA Seminar, 3/96.

Lynch JH. Critical Care Pathways and Quality of Life in Prostate Cancer and BPH. Proceedings from Perspectives in Urology, 12/96

Lynch JH. Minimally Invasive Treatment Options for BPH: TUNA vs. TUMT. Proceedings from Perspectives in Urology, 12/96.

Lynch JH. Outcome Analysis and Critical Pathways for Localized Prostate Cancer. Proceedings from 7<sup>th</sup> International Prostate Cancer Update, 1/97.

Lynch JH. Renal Cell Carcinoma. 1997 International Urology Preceptorship Program, 3/11/97.

Lynch JH. Superficial Bladder Cancer. 1997 International Urology Preceptorship Program, 3/11/97.

Lynch JH. Transurethral Microwave Thermotherapy. 1997 International Urology Preceptorship Program, 3/11/97.

Roberts BJ, Regan JB, Lynch JH, Lau I, Wang JY, Lo S-CB, Mun SK, Hayes WS. Transurethral Microwave thermotherapy; Prediction of Treatment Outcome Using Various analytical Methods. Journal of Urology 157:4; 1706A, 4/97.

Kaplan CR, Lynch JH, Zeng J, Moul JW, Sesterhenn IA, Mun SK. Comparison of Sextant 5-Region Biopsy Technique Using a Three-Dimensional Computer Simulation of Actual Prostate Specimens. J Urol. 159:5; 687A, 6/98.

Kaplan CR, Lynch JH, Zeng J, Moul JW, Sesterhenn IA, Mun SK. Comparison of Needle Core Volume to Tumor Volume Using Three-Dimensional Modeling of Localized Prostate Cancer. J Urol. 159:5, 1146A, 6/98.

Crawford ED, Snow P, Lynch J, McLeod D, Batiello J, Stock R, Stone N, Gamito E, Brandt J. Artificial Intelligence System in Prediction of Lymph Node Involvement in Radical Prostatectomy Patients. J Urol 161:4, 907A, 1999.

Walker JR, Sundaresan P, Rabkin SD, Lynch JH, Martuza RL. A Novel New Treatment for Prostate Cancer with a Conditionally Replicating Herpes Simplex-I Virus, 6207. J Urol 161:4, 473A, 1999.

Cliau DW, Sokoll E, Partin AW, Wong PT, Sasse E, Montie J, Wojno K, Crawford ED, Morel JW, Lynch J, Marley G, Woolf P, Wright G, Vessella R. The Use of 90 Free PSA to Predict Prostate Cancer Probabilities: An Eleven Center Perspective Study Using an Automated Immunoassay System in a Population with Nonsuspicious DRE. J Urol 161:4, 353A, 1999.

Lynch JH, Editorial Review, Glenn's Urologic Surgery. J. Urol. 161:6 1999.

Opell BM, Zeng J, Bauer JJ, Zhang W, Sesterhenn IA, Mun SK, Moul JW, Lynch JH. Correlating The Number of Positive Biopsy Cores To Tumor Volume For Prostate Cancer. J Urol 165:5, 1284A, 2001.

Opell MB, Zeng J, Bauer JJ, Connelly RR, Zhang W, Sesterhenn IA, Mun SK, Moul JW, Lynch JH. Investigating the distribution of prostate cancer using three-dimensional computer simulation. Prostate Cancer and Prostatic Diseases (2002) 5, 204-208.

Stone NN, Crawford Ed, Lynch J, Brawer M, Petrylak DP, Moyad M. Relationships of Life Style with PSA. Testosterone and Cholesterol in a Large Cohort of Men Screened for Prostate Cancer. J Urol 175:5 535A, 2006.

Bonslaver J, Collins S, Lei S, Suy S, Anderson E, Satinsky A, Collins B, Gagnon G, Dritschilo A, Lynch J, McGeagh K. A Novel technique for Prostatic Fiducial Placement. MAAUA 2008.

Kowalczyk KH, Christiansen KA, Lynch JH, Ghasemian R, Verghese M, Hwang JJ. Routine Ureteral Frozen Section Examination at the Time of radical Cystectomy: Utility and Cost-Effectiveness. J Urol 181: 4 551A, 2009.

Blatt AM, Fadahunsi A, Ahn C, Lynch JH, Ghasemian R, Verghese M, Hwang JJ. Surgical Complications Related to Robotic Prostatectomy: Prospective Analysis. J Urol 181:4 1013A, 2009.

Williams RM, Tuong, W, Luta G, Davis K, Lynch J, Ahaghotu C and Taylor KL. Shared decision making preferences and medical trust among men participating in free prostate cancer screening programs. American Society of Preventive Oncology. Bethesda, MD 3/10.

## **B. Grants/Awards/Research Funding:**

### **Current Active**

Flow Cytometric Analysis of Cellular DNA in Paraffin Embedded Prostatic Tissue Biomedical Research Support Grant - \$6,000	1986
National Prostatic Cancer Project Clinical Trials - \$20,000	1983-1986
Besselar - Clinical Trials in Prostate Cancer - \$4,612	1987-1989
Schering Corp. - Effect of Interferon on Resected Renal Cell Carcinoma - \$4,758	1989
Hoechst Pharmaceuticals - Effect of Cefpirome on Urinary Tract Infections - \$15,000	1989
National Institute of Health (CA50229) Polarized Secretion by Prostatic Cells (CO-investigator) - \$380,300	Expired 1992
Fox Prostate Cancer Research Fund Donations & Development Funds with Continuing Development \$800,000	1989-Present
Investigator - FDA Trials Utilizing Thermotherapy (Prostatron) for Treatment of BPH - began 3/91. One of five U.S. University Centers to receive IDE for trials \$100,000	
National Institutes of Health - Role of NGF Peptides and Receptors in BPH R01 DK46051 \$464,944 Co-investigator	9/92-10/95
National Institutes of Health - Role of NGF Receptors in Human Prostate Neoplasia - R01 DK47508 \$671,106 Co-investigator	9/93-9/96
Study in the Treatment of Recurrent Bladder Tumors following BCG Therapy Schering Pharmaceuticals \$20,000	1994-1996

Evaluation of the Clinical Effectiveness and Cost-Effectiveness of Terazosin vs. Placebo in the Treatment of Patients with Symptomatic Benign  Prostatic Hyperplasia (BPH) Abbott Laboratories \$34,950	1994-1006
The Long-Term Safety and Efficacy of Terazosin Administered once daily for Treatment of Symptomatic Benign Prostatic Hyperplasia: An Extension of Study M91-639R Abbott Laboratories \$24,750	1995-1997
Safety and Efficacy of a Four-Month Depot Formulation of Leuprolide in Patients with Stage D2 Prostatic Adenocarcinoma Tap Pharmaceuticals \$14,000	1997
Assessment of Health-Related Quality of Life in Patients with Stage D2 Prostate Cancer in Remission and Progression Premier Health Alliance, Inc., Schering Laboratories \$4,000	1997
Abbott - Long-term Safety and Efficacy of Terazosin Administered Once Daily for Treatment of Symptomatic Benign Prostatic Hyperplasia: An Extension of Study M91-639-R Total - \$7,300	1996-1997
Abbott - Establishment of a Serum Bank for the Evaluation of Prostate Cancer, Benign Prostatic Hypertrophy (BPH), and Other Urologic Conditions. Total - \$36,000	1996
Abbott - Prostate Cancer Screening 1996: Analysis of Demographics, PSA Results, DRE Results and Follow-up Evaluation. Total - \$36,000	1996
Abbott - Abbott AxSym Free PSA: A Study to Evaluate the Use of the Free/Total PSA as an Aid to Identify Prostate Cancer in Men Undergoing Evaluation for Prostate Abnormalities. Estimated Total - \$10,000	1997-Present
Zeneca - A Randomized Double-Blind Comparative Trial of Bicalutamide (Casodex) versus Placebo in Patients with Early Prostate Cancer. Total - \$38,000	1997-Present
Schering - Comparative Study of the Clinical Efficacy of Two Dosing Regimens of Eulexin. Total \$4,000	1998
CDC Cooperative Agreement Improving Black Men's Knowledge Of The Prostate Cancer Screening Dilemma. Co-investigator \$250,000	9/30/98-10/30/01



National Institute of Health  
NGF Receptor, Regulations of Prostate Growth. ROIDK52626  
\$458,979 Co-investigator

EDAP Technomed - High Intensity Focused Ultrasound in 1999  
the Treatment of Patients with Radiation Recurrent Prostate Cancer - \$50,000.

DOD (DAMD17-02-1-0062) Co-Investigator  
Treatment Decision Making in Early-Stage Prostate Cancer: Evaluation of Computer Based Patient  
Education and Interactive Decision Aid. 2/02-1/06 \$580,714.

NIH (R01 CA098967-02) Co-Investigator  
Prostate Cancer Screening: Fostering Informed Decisions. 9/1/03-8/31/06. \$1,130, 521.

Principal Investigator – High Intensity Focused Ultrasound in the treatment of newly diagnosed prostate  
cancer – Healthtronics – 2006

NCI/ NIH Grant (R01 CA 155578-04)- 8/27/2014 Funding Start Date  
Treatment Decisions and Patient Reported Outcomes in Low Risk Prostate Cancer  
Total Grant was for \$97,697.

### **3. TEACHING, MENTORING, AND ADVISING**

#### **A. Teaching Activities**

##### **i. Medical School Courses**

Name and Course Number: Surgical Specialties Clerkship

Role: Course Director

Year(s) Taught: 2004-2015

Number of Students: All

Overall Evaluation Score: 4

Name and Course Number: Clinical Anatomy of the Male Pelvis

Role: Lecturer

Number of Direct Contact Hours\*: 1

Year Taught: 2006-2015

Number of Students: All

### **4. SERVICE**

#### **A. University Service:**

Interviewer, Committee on Admissions 1979-1984,  
Georgetown Medical School 1999

Founder's Day Committee 1983

Committee to Evaluate Ophthalmology 1983

Ad Hoc Committee on Tenure	1986
Clinical Science Building Subcommittee	1986
Utilization Management Committee	1982-1990
Chairman, Utilization Committee	1984-1990
Prospective Payment/Quality, Assurance Coordinating Group	1985-1990
Laser Committee	1985-1995
Chairman, Committee to Evaluate Radiation Oncology	1990
Executive Staff	1984-1990
Committee on Faculty	1989-1993
Value Analysis Committee	1991-1992
Faculty Practice Group	1992-1994 1998-Present
Committee on Clinical Practice	1992
Chairman, Clinical Service Standards Committee	1990-1998
Cancer Committee	1994-Present
Post-Graduate Medical Education Committee	1994-Present
Quality Council	1995-1998
Clinical Revenue Task Force	1997
Medical Alumni Task Force	1997
Co-Chair: Task Force on Patient Flow/Information	1997
Search Committee - Ob/Gyn	1997
Committee on Faculty	1996-1998
University Campaign Steering Committee	1998-2004
Chairman, Faculty Practice Group Restructuring Committee	1999

Committee on Medical Education	1999-Present
Medical Director of Perioperative Services, Georgetown University Hospital	1998–2002
Chairman, Medical Executive Committee; Georgetown University Hospital	2000–2002
President, Medical Staff, Georgetown University Hospital	2000-2002
Co-Chairman, Committee on Medical Education	2001-Present
Medical Center EVP Search Committee	2002, 2006
Committee on Students	2004-Present
Clinical Clerkship Subcommittee	2004-2015
Surgical Specialty Clerkship Director	2004-2015
Medical Director Peri-Operative Services	2016
<b>B. Professional Service:</b>	
Co-Chairman, Genitourinary Committee, Mid-Atlantic Oncology Program	1983-1986
Principle Investigator, National Prostatic Cancer Project	1983-1986
Consulting Editor - Monographs in Urology	1984-1988
Prof. Education Comm. - D.C. Chapter, American Cancer Society	1982
Executive Committee, Georgetown Clinical Society	1982-1988
Pharmacy and Therapeutics Committee, Sibley Hospital	1983
Library Committee, Sibley Hospital	1984-1987
Criteria Review Panel, D.C. Medical Society, Delmarva	1985-1988
American College of Surgeons Representative Medical Advisory Panel to Department of Defense	1985-1989
D.C. Hospital Consortium on Utilization Review	1987-1990
Chairman, D.C. Hospital Consortium on Utilization Review	1989-1990
Program Chairman, Metro. Chapter ACS Annual Meeting	1987

Education Committee, Mid-Atlantic Section, AUA	1988-1990
Executive Committee, Metro. Chapter ACS	1988-1990
Treasurer, Washington Urologic Society	1989
Secretary, Washington Urologic Society	1990
Vice President, Washington Urologic Society	1991
Nominating Committee, Mid-Atlantic Section, AUA	1990
Program Chairman, Mid-Atlantic Section, AUA Annual Meeting Richmond, VA	1990
AUA Today Editorial Board	1990-1991
Reviewer, Journal of Urology	1990-Present
Reviewer, Urology	1992-Present
Reviewer, Cancer	1997
Co-Chairman - "Progress Report on the Clinical Treatment of Prostate Cancer," Colorado Springs, Colorado, Scottsdale, Arizona	1990 1990
Co-Chairman - "Update in the Treatment of Prostate Disease" Toronto, Canada	1990
Chairman - "Current Perspectives in the Management of Prostate Diseases," Washington, D.C.	1990
Chairman - "Advances in the Management of Prostatic Diseases Washington, D.C.	1990
Chairman - "Update in the Treatment of Prostatic Malignancy Chantilly, VA	1990
Chairman - "Controversies in Prostate Cancer – Diagnosis and Treatment" Orlando, Florida	1991
Executive Committee, Mid Atlantic Section, AUA	1991-1994
President, Washington Urologic Society	1992

Ad Hoc Study Section, NIDDK	1992
CME Advisory Board, Discovery International	1993-2004
Chairman, CME Advisory Board, Discovery International	1996-1998
Chairman, Urologic Advisory Council: Future Research and Direction Abbott Park, Illinois	4/93
Education Council, AUA	1995-2000
Board Member - UMAC Association	1994-1997
Medical Advisory Board - EDAP - Technomed	1997-2002
Moderator - Heat Techniques in BPH. World Congress of Endourology, New York, New York	9/4/98
Practice Guidelines Committee – AUA	2001-2004
AUA Liaison to the FDA	2002-2003
Local Arrangement Committee Chairman, Mid-Atlantic AUA Meeting	2001, 2004
Credentials Committee, Wash. Chapter, American College Surgeons	2001-Present
Richard J Fox Foundation Board	1992-Present
Mid-Atlantic Section AUA Alternate Representative Board of Directors	May 2006 – 2009
Executive Committee – Society of Urology Chairs & Program Directors	2007-2010
Mid-Atlantic Section AUA Board of Directors	2010-2014
Board of Directors – American Urological Association	2010-2014
Finance Committee AUA	2011-2014
Chair, Compensation Committee, AUA	2011-2014
Chair, Public Educational Task Force, Urology Care Foundation	2015-Present
Publication Committee, AUA	2015-Present
Editor, Urology Health Extra	2015-Present

Moderator - Podium Session, AUA Annual Meeting	2013-Present
--	--------------

President, Mid Atlantic Section AUA	2014-2015
-------------------------------------	-----------

Past President Mid Atlantic Section AUA	2015-2016
---	-----------

## 5. HONORS AND AWARDS

Alpha Omega Alpha	1973
-------------------	------

Who's Who - Professionals and Executives	1994-Present
--	--------------

Washingtonian Magazine Top Doctors Best Doctors in America	1994-Present
---	--------------

Georgetown University Vicennial Medal	1999
---------------------------------------	------

Kaiser Permanente Teaching Award, Georgetown University School of Medicine	2008
---	------

Magis Award – Master Teacher, Georgetown University Medical Center	2009
---	------

Georgetown University School of Medicine Founders Medal	2010
---	------

## 6. PROFESSIONAL SOCIETY MEMBERSHIP

Diplomat - National Board of Medical Examiners	1974
--	------

American Medical Association	1979-1981 1991-1995
------------------------------	------------------------

D.C. Medical Society	1979-1981
----------------------	-----------

Washington Urologic Society	1979-Present
-----------------------------	--------------

Mid-Atlantic Section, American Urologic Association	1981-Present
---	--------------

American Urologic Association	1982-Present
-------------------------------	--------------

Metro Chapter, American College of Surgeons	1982-Present
---	--------------


American College of Surgeons	1982-Present
------------------------------	--------------

Society of Academic Surgeons	1983-1987
------------------------------	-----------

Georgetown Clinical Society	1979-1989
Society of University Urologists	1988-Present
Society of Urologic Oncology	1986-Present
Washington Academy of Surgery	1990-Present
National Kidney Foundation	1990-2002

*I certify that this curriculum vitae is a current and accurate statement of my professional record.*

Signature:



Date: 11/21/16